Do Targeted Therapies Drive Disparities?


After the widespread use of targeted therapies for breast cancer treatment, there was a wider gap in mortality rates between black and white women with the disease.

After the implementation of targeted therapies, researchers saw a larger gap in breast cancer mortality rates between African American and Caucasian women, according to Melissa B. Davis, PhD, an assistant professor at Weill Cornell Medicine.

Targeted therapies caused a decline in deaths in white women, while deaths in black women essentially stayed the same. Some of this can be attributed to access to healthcare, but upon further investigation, researchers also found that the 2 groups have differences in their tumor biology and types of breast cancer, thus making these new treatments more efficacious in the Caucasian population.

Recent Videos
Meaghan Mooney, B.S.N., RN, OCN, during the Extraordinary Healer interview
Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
Alison Tray, of Hartford Healthcare, discusses her team's research on a multidisciplinary team approach to manage the cancer drug shortage
Related Content
© 2024 MJH Life Sciences

All rights reserved.